Status: Enrolling
Investigator: Jasleen Randhawa
Study Coordinator: Michelle Guthrie
Phone: 713.441.6564
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will ... Read more >
Status: Enrolling
Investigator: Lawrence Rice
Study Coordinator: Minh Truong
Phone: 346.238.6403
Study AG348-C-006 will evaluate the efficacy and safety of orally administered AG-348 as compared with placebo in participants with pyruvate kinase deficiency (PKD), who are not regularly receiving blood transfusions. Participants will be random ... Read more >
Status: Enrolling
Investigator: Lawrence Rice
Study Coordinator: Minh Truong
Phone: 346.238.6403
This study will assess the ability of eltrombopag to induce sustained treatment-free remission in ITP subjects who relapsed or failed to respond to an initial treatment with steroids. There is limited, mainly retrospective evidence that earli ... Read more >
Status: Enrolling
Investigator: Brian Bruckner
Study Coordinator: Deborah Barr
Phone: 713.441.3916
This study is evaluating the effectiveness of PleuraFlow System Active Clearance Technology (ACT) in the management of blood evacuation. The Pleuraflow System ACT is a guided wire with a distal loop that rests at the end of a chest tube. The sys ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Michelle Guthrie
Phone: 713.441.6564
Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typ ... Read more >
Status: Open Not Enrolling
Investigator: Jasleen Randhawa
Study Coordinator: Michelle Guthrie
Phone: 713.441.6564
Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine ... Read more >
Status: Open Not Enrolling
Investigator: Alpesh Shah
Study Coordinator: Patricia Brinegar
Phone: 713.441.3506
This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and OUS. A minimum of 40% of total patients will be enrolled in the US. This study will enroll patient ... Read more >
Status: Enrolling
Investigator: Alan Lumsden
Study Coordinator: Kim Donlon
Phone: 713.441.9394
This prospective, multicenter, single-arm clinical study will further evaluate the safety and effectiveness of Cook's permanent and retrievable inferior vena cava (IVC) filters (specifically, the Günther Tulip® Vena Cava Filter and Cook Celect® ... Read more >
Status: Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Syed Muhammad Saad
Phone: 281.276.5263
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remissi ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Michelle Guthrie
Phone: 713.441.6564
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >
